This is a prospective pilot study to assess the plasma levels of particular proteins involved
in the transforming growth factor beta (TGF-β) pathway and its down stream regulators, CHIP,
as well as micro RNA molecules in subjects with pulmonary arterial hypertension (PAH) and
compare them to control subjects without PAH to see if they can be used as a diagnostic or
prognostic marker of PAH and how this compares to other diagnostic biomarkers N-terminal
pro-natriuretic peptide (NT Pro-BNP) and C-reactive protein (CRP).
Study ROR-PH-301, ADVANCE OUTCOMES, is designed to assess the efficacy and safety of
ralinepag when added to pulmonary arterial hypertension (PAH) standard of care or
PAH-specific background therapy in subjects with World Health Organization (WHO) Group 1 PAH.
The primary purpose of this study is to estimate the percentage of participants in the
population considered clinically as not having pulmonary hypertension (PH) that are positive
for PH biomarker (micro ribonucleic acid [RNA]); estimate the percentage of participants in
the population considered clinically as not having PH that are positive for PH by cardiac
magnetic resonance imaging (MRI) and compare results of the MRI to the biomarker results; to
determine the performance of the biomarker signatures identified in the CIPHER (NAPUH0001)
study in terms of sensitivity, specificity, positive predictive value (PPV) and negative
The primary purpose of this study is to identify and develop biomarker signatures based on
circulating micro ribonucleic acid (RNA) in the blood samples associated with high risk of
pulmonary hypertension (PH) to assist in the diagnosis of PH; to estimate the sensitivity,
specificity, positive predictive value, and negative predictive value of the biomarker
signatures in identifying participants with PH by comparing the biomarker signatures to right
heart catheterization (RHC) and to compare the sensitivity, specificity, positive predictive
value, and negative predictive value of the biomarker signatures with the sensitivity,
Oral selexipag is commercially available in several countries for the treatment of a
particular group of pulmonary hypertension (PH) called pulmonary arterial hypertension (PAH).
The aim of the present study is to investigate whether selexipag could be helpful to treat
patients with another form of PH called sarcoidosis-associated pulmonary hypertension (SAPH).
A Randomized, Placebo-Controlled, Double-blind, Dose Escalation Study to Assess Safety,
Efficacy and Pharmacokinetics of GMA301 Injection in Subjects with Pulmonary Arterial
This is an open-label, single-center study to examine distinguishing features of the
structure and function of the oral and gut microbiome in healthy adult normal volunteers
compared to volunteers with PH-HFpEF in the breakdown of oral nitrate.
The purpose of the study is to evaluate the change from baseline to 12 months after study
enrollment in the number of the following non-invasive risk criteria: World Health
Organization Functional Class (WHO/FC), 6-minute walk distance (6MWD), Brain Natriuretic
Peptide (BNP) or N-terminal pro-brain Natriuretic Peptide (NT-proBNP).
Study ROR-PH-302, ADVANCE CAPACITY, is designed to evaluate the effects of ralinepag therapy
on exercise capacity as assessed by change in peak oxygen consumption (VO2) derived from
cardiopulmonary exercise testing (CPET) after 28 weeks of treatment
The purpose of this study is to assess the safety and efficacy of Rodatristat Ethyl in
pulmonary arterial hypertension (PAH) patients.